131.87
0.00 (0.00%)
| Penutupan Terdahulu | 131.87 |
| Buka | 131.90 |
| Purata Dagangan (3B) | 2,731,608 |
| Modal Pasaran | 14,047,055,872 |
| Harga / Pendapatan (P/E Ke hadapan) | 158.73 |
| Harga / Jualan (P/S) | 19.89 |
| Harga / Buku (P/B) | 12.15 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 May 2025 - 9 May 2025 |
| Margin Keuntungan | -10.97% |
| Margin Operasi (TTM) | -14.65% |
| EPS Cair (TTM) | -0.720 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 50.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.48% |
| Nisbah Semasa (MRQ) | 6.36 |
| Aliran Tunai Operasi (OCF TTM) | -73.18 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -63.55 M |
| Pulangan Atas Aset (ROA TTM) | -6.96% |
| Pulangan Atas Ekuiti (ROE TTM) | -8.58% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Menaik | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Menaik | Bercampur | |
| Stok | Intra-Cellular Therapies Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | -5.0 |
| Osilator Teknikal | 0.0 |
| Purata | -0.88 |
|
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 3.27% |
| % Dimiliki oleh Institusi | 96.54% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |